Skip to main content
SpringerLink
Log in

Evaluation of the Effectiveness of Imiquimod and 5-Fluorouracil for the Treatment of Actinic Keratosis: Critical Review and Meta-analysis of Efficacy Studies

  • Review
  • Published:
Journal of Cutaneous Medicine and Surgery

Abstract

Background:

Actinic keratosis lesions occur frequently on sun-exposed skin of Caucasians. They become more prevalent with advancing age and are important in identifying the risk factor of those people possibly predisposed to invasive squamous cell carcinoma. Topical therapies are useful alternatives to cryotherapy for treating diffuse actinic damage and a number of preparations have been developed for treating actinic keratosis.

Objectives:

A cumulative meta-analysis was performed to determine the efficacy of imiquimod 5% cream, which presents a new alternative topical therapy for actinic keratosis, and to compare it to 5-fluorouracil for the treatment of actinic keratosis lesions of the face and scalp.

Methods:

We searched MEDLINE (1966 to October 2004) for relevant studies evaluating the efficacy of actinic keratosis topical agents imiquimod and 5-fluorouracil (0.5%, 1%, and 5%). Studies included in this meta-analysis required a dosage regimen that was not significantly different from that approved by Health Canada and the U.S. FDA. Studies also required a well-defined treatment duration and followup period, with the primary efficacy variable being the complete (100%) clearance of all actinic keratosis lesions defined as the proportion of patients at followup with no clinically visible lesions in the treatment area. To determine the average efficacy rate for both drugs, the data from each study were combined for that drug.

Results:

Ten studies were included in the analysis. The average efficacy rate for each drug (with 95% confidence interval) was 5-fluorouracil, 52 ± 18% (n = 6 studies, 145 subjects) and imiquimod, 70 ± 12% (n = 4 studies, 393 subjects).

Conclusions:

The results of this meta-analysis show that both imiquimod and 5-fluorouracil are effective methods for the treatment of actinic keratosis and provide a useful alternative to cryotherapy. However, this analysis suggests that imiquimod may have higher efficacy than 5-fluorouracil for actinic keratosis lesions located on the face and scalp and therefore provides another option to dermatologists.

Antécédents:

L’apparition de lésions de kératose actinique sur la peau de sujets blancs est fréquente après l’exposition au soleil. Avec l’âge, ces lésions qui deviennent plus. répandues sont importantes dans 1’identification des facteurs de risque chez les sujets qui seraient prédisposes à être victimes d’une invasion de careinomes squameux. Les thérapies topiques sont des alternatives utiles à la cryotherapie dans le traitement des lésions actiniques diffuses. Un nombre de produits formulés ont êtê mis au point pour le traitement de la kératose actinique.

Objectifs:

Une méta-analyse cumulative a été effectuée en vue de déterminer 1’efficacité de la crème d’imiquimod à 5%, qui représente une nouvelle therapie topique alternative de la kératose actinique, et de la comparer à 5-fluorouracil dans le traitement des lésions de kératose actinique sur le visage et le cuir chevelu.

Méthodes:

Nous avons cherché dans MEDLINE (de 1966 jusqu’à octobre 2004) les études pertinentes qui évaluent l’efficacité des agents topiques imiquimod et 5-fluorouracil (0.5%, 1%, et 5%) dans le traitement des kératoses actiniques. Les études dont la présente méta-analyse tient compte suivent un dosage peu différent du dosage approuvé par Sante Canada et la FDA aux États-Unis. Les études doivent également comprendre une durée de traitement bien définie et une période de suivi. La principale variable d’efficacité est 1’épuration totale de la peau (100%) de toutes les lésions actiniques, définie comme la proportion de patients qui, au suivi, ne présentait aucune trace de lésions dans la zone traitée. Afin de déterminer le taux d’efficacité moyen de chacun des deux médicaments, les données de chaque étude ont été combinées.

Résultats:

Dix études ont été comprises dans 1’analyse. Le taux d’efficacite moyen de chaque médicament (avec un intervalle de confiance de 95%) est:5-fluorouracil, 52 ± 18% ( n = 6 études, 145 sujets) et imiquimod, 70 ± 12% (n = 4 etudes, 393 sujets).

Conclusion:

Les résultats de cette méta-analyse montrent que l’imiquimod et 5-fluorouracil sont tous deux efficaces dans le traitement des kératoses actiniques et représentent des alternatives utiles à la cryothérapie. Toutefois, cette étude suggère que l’imiquimod serait plus efficace que 5-fluorouracil dans le traitement des lésions de kératose actinique qui se trouvent sur le visage et le cuir chevelu, et représenterait done une autre option de traitement pour les dermatologues.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Feldman SR, Fleischer AB Jr, McConnell RC. Most common dermatologic problems identified by internists, 1990–1994. Arch Intern Med 1998; 158:726–730

    Article  PubMed  CAS  Google Scholar 

  2. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002; 70:30–36

    PubMed  Google Scholar 

  3. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42:8–10

    Article  PubMed  CAS  Google Scholar 

  4. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42:4–7

    Article  PubMed  CAS  Google Scholar 

  5. Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000; 42:25–28

    Article  PubMed  CAS  Google Scholar 

  6. Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol 1995; 32:95–98

    CAS  Google Scholar 

  7. Feldman SR, Fleischer AB Jr, Williford PM, et al. Destructive procedures are the standard of care for treatment of actinic keratoses. J Am Acad Dermatol 1999; 40:43–47

    Article  PubMed  CAS  Google Scholar 

  8. Marks R. The role of treatment of actinic keratoses in the prevention of morbidity and mortality due to squamous cell carcinoma. Arch Dermatol 1991; 127:1031–1033

    Article  PubMed  CAS  Google Scholar 

  9. Dillaha CJ, Jansen GT, Honeycutt WM, et al. Further studies with topical 5-fluorouracil. Arch Dermatol 1965; 92:410–417

    Article  PubMed  CAS  Google Scholar 

  10. Gupta AK, Weiss JS, Jorizzo JL. 5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. Skin Therapy Lett 2001; 6:1–4

    PubMed  CAS  Google Scholar 

  11. Jansen GT. Topical therapy with 5-fluorouracil. J Surg Oncol 1971; 3:317–323

    PubMed  CAS  Google Scholar 

  12. Jeffes EW III, Tang EH. Actinic keratosis. Current treatment options. Am J Clin Dermatol 2000; 1:167–179

    Google Scholar 

  13. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis 2002; 70:335–339

    PubMed  Google Scholar 

  14. Rossman RE. Topical fluorouracil therapy. South Med J 1969; 62:1240–1242

    PubMed  CAS  Google Scholar 

  15. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002; 70:22–29

    PubMed  Google Scholar 

  16. Eaglstein WH, Weinstein GD, Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol 1970; 101:132–139

    Article  PubMed  CAS  Google Scholar 

  17. Dahl MV. Imiquimod: an immune response modifier. J Am Acad Dermatol 2000; 43:S1–S5

    Article  PubMed  CAS  Google Scholar 

  18. Dahl MV. Imiquimod: a cytokine inducer. J Am Acad Dermatol 2002; 47:S205–S208

    Article  PubMed  Google Scholar 

  19. Del Rosso JQ. An update on newer topical therapies for actinic keratoses: advances and applications. J Drugs Dermatol 2003; 2:35–39

    PubMed  Google Scholar 

  20. Stanley MA. Mechanism of action of imiquimod. Papillomavirus Rep. 1999; 10:23–29

    Google Scholar 

  21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–188

    Article  PubMed  CAS  Google Scholar 

  22. Velanovich V. Meta-analysis for combining Bayesian probabilities. Med Hypotheses 1991; 35:192–195

    Article  PubMed  CAS  Google Scholar 

  23. Breza T, Taylor R, Eaglstein WH. Noninflammatory destruction of actinic keratoses by fluorouracil. Arch Dermatol 1976; 112:1256–1258

    Article  PubMed  CAS  Google Scholar 

  24. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51:547–555

    Article  PubMed  Google Scholar 

  25. Lawrence N, Cox SE, Cockerell CJ, et al. A comparison of the efficacy and safety of Jessner’s solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995; 131:176–181

    Article  PubMed  CAS  Google Scholar 

  26. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50:714–721

    Article  PubMed  Google Scholar 

  27. Shuttleworth D, Marks R. A comparison of the effects of intralesional interferon alpha-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen’s disease. J Dermatol Treat 1989; 1:65–68

    Google Scholar 

  28. Stockfleth E, Meyer T, Benninghoff B, et al. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 144:1050–1053

    Article  PubMed  CAS  Google Scholar 

  29. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002; 138:1498–1502

    Article  PubMed  CAS  Google Scholar 

  30. Abadir DM. Combination of topical 5-fluorouracil with cryotherapy for treatment of actinic keratoses. J Dermatol Surg Oncol 1983; 9:403–404

    PubMed  CAS  Google Scholar 

  31. Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double-blind controlled study. Br J Dermatol 1987; 116:549–552

    Article  PubMed  CAS  Google Scholar 

  32. Bianchi L, Campione E, Marulli GC, et al. Actinic keratosis treated with an immune response modifier: a ease report of six patients. Clin Exp Dermatol 2003; 28(Suppl 1):39–41

    Article  PubMed  Google Scholar 

  33. Chen K, Yap LM, Marks R, et al. Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas J Dermatol 2003; 44:250–255

    Article  PubMed  Google Scholar 

  34. Eklind J, Tartler U, Maschke J, et al. Imiquimod to treat different cancers of the epidermis. Dermatol Surg 2003; 29:890–896

    Article  PubMed  Google Scholar 

  35. Epstein E. Treatment of lip keratoses (actinic cheilitis) with topical fluorouracil. Arch Dermatol 1977; 113:906–908

    Article  PubMed  CAS  Google Scholar 

  36. Kurwa HA, Yong-Gee SA, Seed PT, et al. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999; 41:414–418

    Article  PubMed  CAS  Google Scholar 

  37. Labandeira J, Pereiro M Jr, Valdes F, et al. Intermittent topical 5-fluorouracil is effective without significant irritation in the treatment of actinic keratoses but prolongs treatment duration. Dermatol Surg 2004; 30:517–520

    Article  PubMed  Google Scholar 

  38. Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24:990–1000

    Article  PubMed  CAS  Google Scholar 

  39. Pearlman DL. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 1991; 25:665–667

    Article  PubMed  CAS  Google Scholar 

  40. Persaud A, Lebwohl M. Imiquimod cream in the treatment of actinic keratoses. J Am Acad Dermatol 2002; 47:S236–S239

    Article  PubMed  Google Scholar 

  41. Persaud AN, Shamuelova E, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002; 47:553–556

    Article  PubMed  Google Scholar 

  42. Robins P. Pulse therapy with 5-FU in eradicating actinic keratoses with less than recommended dosage. J Drugs Dermatol 2002; 1:25–30

    PubMed  Google Scholar 

  43. Robinson TA, Kligman AM. Treatment of solar keratoses of the extremities with retinoic acid and 5-fluorouracil. Br J Dermatol 1975; 92:703–706

    Article  PubMed  CAS  Google Scholar 

  44. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. J Am Acad Dermatol 2002; 47:571–577

    Article  PubMed  Google Scholar 

  45. Smith S, Piacquadio D, Morhenn V, et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003; 2:629–635

    PubMed  Google Scholar 

  46. Warnock GR, Fuller RP Jr, Pelleu GB Jr. Evaluation of 5-fluorouracil in the treatment of actinic keratosis of the lip. Oral Surg Oral Med Oral Pathol 1981; 52:501–505

    Article  PubMed  CAS  Google Scholar 

  47. Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam Consultation on Meta-Analysis. J Clin Epidemiol 1995; 48:167–171

    Article  PubMed  CAS  Google Scholar 

  48. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001; 323: 42–46

    Article  PubMed  CAS  Google Scholar 

  49. Mulrow C, Langhorne P, Grimshaw J. Integrating heterogeneous pieces of evidence in systematic reviews. Ann Intern Med 1997; 127:989–995

    PubMed  CAS  Google Scholar 

  50. Silapunt S, Goldberg LH, Alam M. Topical and light-based treatments for actinic keratoses. Semin Cutan Med Surg 2003; 22:162–170

    Article  PubMed  Google Scholar 

  51. Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther 2001; 23:908–920

    Article  PubMed  CAS  Google Scholar 

  52. Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5% fluorouracil formulations with that of a 5% formulation. Clin Ther 2001; 23:901–907

    Article  PubMed  CAS  Google Scholar 

  53. Levy S, Furst K, Chern W. A novel 0.5% fluorouracil cream is minimally absorbed into the systemic circulation yet is as effective as 5% fluorouracil cream. Cutis 2002; 70:14–21

    PubMed  Google Scholar 

  54. Simmonds WL. Topical management of actinic keratoses with 5-fluorouracil: results of a 6-year follow-up study. Cutis 1972: 10:737–742

    Google Scholar 

  55. Robins P, Gupta AK. The use of topical fluorouracil to treat actinic keratosis. Cutis x2002; 70:4–7

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Dermatology, Department of Medicine, Sunnybrook and Women’s College Health Science Center (Sunnybrook site) and the University of Toronto, Toronto, Canada

    Aditya K. Gupta

  2. Mediprobe Research Inc., London, Ontario, Canada

    Aditya K. Gupta, Valerie Davey & Heather Mcphail

  3. Aditya K. Gupta, 645 Windermere Road, N5X 2P1, London, Ontario, Canada

    Aditya K. Gupta

Authors
  1. Aditya K. Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valerie Davey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heather Mcphail
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aditya K. Gupta.

Additional information

Supported in part by 3M Pharmaceuticals, London, Ontario, Canada.

Dr. Gupta has acted as an advisor and conducted clinical trials for 3M Pharmaceuticals, London, Ontario, Canada.

About this article

Cite this article

Gupta, A.K., Davey, V. & Mcphail, H. Evaluation of the Effectiveness of Imiquimod and 5-Fluorouracil for the Treatment of Actinic Keratosis: Critical Review and Meta-analysis of Efficacy Studies. J Cutan Med Surg 9, 209–214 (2005). https://doi.org/10.1007/s10227-005-0148-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10227-005-0148-6

Keywords

Search

Navigation